---
document_datetime: 2025-07-10 13:19:25
document_pages: 32
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/synjardy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: synjardy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 16.4963548
conversion_datetime: 2025-12-28 00:06:35.083944
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Synjardy

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                             |
|----------------------|----------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10388 /202404  | Periodic Safety Update EU Single assessment - empagliflozin, empagliflozin / metformin | 12/12/2024                          | 07/02/2025                                  | SmPC                             | • In view of available data on the risk of 'necrotizing fasciitis of the perineum (Fournier´s gangrene)' from the literature and spontaneous reports of Fournier´s gangrene reported in non-diabetic population and in view of a plausible mechanism of action, the PRAC considers that there is sufficient evidence to justify an amendment of the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| product information in order to indicate that this ADR can occur irrespective of the indication. The PRAC concluded that the product information of products containing empagliflozin should be amended accordingly.  - In view of the available data on phimosis from spontaneous reports and the plausible mechanism of action, PRAC considers there is sufficient evidence to justify an amendment of the product information to hightlight that genital infections may result in phimosis that can require circumcision. The PRAC concluded that the product information of products containing empagliflozin should be amended accordingly.  - In view of the available data on haematocrit increased/polycythaemia from the literature and spontaneous reports and the plausible mechanism of action, the PRAC considers there is sufficient evidence to justify an amendment of section 4.4 of the SmPC  to reflect that patients with pronounced elevations in haematocrit should be monitored and investigated for underlying haematological disease. The PRAC concluded that the product information of products containing empagliflozin should be amended accordingly.  - In view of the available data on prolonged ketoacidosis and prolonged glucosuria from the literature and spontaneous reports, the PRAC considers there is sufficient evidence to justify an amendment of section 4.4 of the SmPC related to the warning on ketoacidosis to indicate that ketoacidosis may be prolonged after discontinuation of empagliflozin in some patients. The PRAC concluded that the product information of products   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             | containing empagliflozin should be amended accordingly.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------|
| WS/2713   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 28/11/2024 | n/a        |             |                                                           |
| II/0078   | Extension of indication to include the treatment of children aged 10 years and above with type 2 diabetes for Synjardy, based on the final results from study 1218-0091 (DINAMO) - A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 16.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 19/09/2024 | 04/11/2024 | SmPC and PL | Please refer to Scientific Discussion \"h-3770-II-78-en\"   |
| IB/0081/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/08/2024 | n/a        |             |                                                           |

<div style=\"page-break-after: always\"></div>

|           | B.II.z - Quality change - Finished product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                        |            |            |    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| N/0079    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                               | 29/07/2024 | 04/11/2024 | PL |
| WS/2571   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                    | 13/06/2024 | n/a        |    |
| IG/1700/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 16/01/2024 | n/a        |    |
| WS/2567   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                  | 05/10/2023 | n/a        |    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0074   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 13/09/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| WS/2450/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to modify administration instructions to the elderly, amend an existing warning for the elderly and remove the warning for 'Cardiac Failure' in order to align with the Jardiance Product Information; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Update of section 4.4 of the SmPC in order to introduce a rewording related to use in patients with type 1 diabetes in order to align with the Jardiance Product Information; the Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 20/07/2023 | 30/08/2023 | SmPC and PL | This variation concerned the alignment of Glyxambi and Synjardi's SmPC and Package Leaflet with that of Jardiance's, following the approval of Jardiance in the treatment of heart failure. This indication was based on the submission of data from trials EMPEROR-Preserved and EMPEROR-Reduced trial, in which most patients were elderly (≥65 years old). After the completion of both EMPEROR trials, where 483 patients aged 85 years and older were included, it has been agreed that the information on the use of empaglifozin in elderly patients is no longer limited. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| IA/0073   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                  | 14/07/2023   | n/a        |             |               |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------|
| WS/2492   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission the competent authority     | 15/06/2023   | n/a        |             | of studies to |
| IG/1617   | B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation                                                                                                                                  | 01/06/2023   | n/a        |             |               |
| WS/2410   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 16/03/2023   | n/a        |             |               |
| WS/2377   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on Vitamin B12 decrease or                                 | 02/03/2023   | 30/08/2023 | SmPC and PL |               |

<div style=\"page-break-after: always\"></div>

|                     | deficiency and to update the list of adverse drug reactions (ADRs) in accordance with the recent update of the PI for Glucophage, which is the reference label for the compound metformin, and following the request by MHRA on 20 June 2022 for all products containing metformin; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| WS/2406             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                      | 09/02/2023 | n/a |                                   |
| PSUSA/10388 /202204 | Periodic Safety Update EU Single assessment - empagliflozin, empagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 01/12/2022 | n/a | PRAC Recommendation - maintenance |
| IB/0066/G           | This was an application for a group of variations. B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product) of a specification parameter wit its                                                                                                                                                                                                                                                                                                                                                          | 23/11/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | corresponding test method as a result of a safety or quality issue B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test   |            |     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/2196 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/06/2022 | n/a |

<div style=\"page-break-after: always\"></div>

| WS/2223/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                        | 07/04/2022   | n/a        |             |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|
| WS/2171     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To update section 4.8 of the SmPC and section 4 of the PL to include the side effect 'constipation'. In addition, the following ADR have been updated in section 4.8: - for Glyxambi: 'Necrotising fasciitis of the perineum (Fournier´s gangrene)' from 'not known' to 'rare'; 'Volume depletion', to add a footnote to indicate that studies with empagliflozin in patients with heart failure showed a higher frequency of volume depletion ('very common') in patients with heart failure where half of the patients had type 2 diabetes mellitus. - for Synjardy: 'Necrotising fasciitis of the perineum | 24/03/2022   | 23/01/2023 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                     | (Fournier´s gangrene)' from 'not known' to 'rare'; 'Angioedema' from 'not known' to 'uncommon'; 'Volume depletion', to add a footnote to indicate that studies with empagliflozin in patients with heart failure showed a higher frequency of volume depletion ('very common') in patients with heart failure where half of the patients had type 2 diabetes mellitus. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10388 /202104 | Periodic Safety Update EU Single assessment - empagliflozin, empagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                                                  | 16/12/2021 | 04/03/2022 | SmPC and PL | Taking into account the PRAC Assessment Report on the PSUR(s) for empagliflozin, empagliflozin / metformin, the scientific conclusions of CHMP are as follows: In view of available data on tubulointerstitial nephritis from the literature and spontaneous reports highly suggestive of causality association including a close temporal relationship and a positive dechallenge, the PRAC considers a causal relationship between empagliflozin, empagliflozin/metformin and tubulointerstitial nephritis is at least a reasonable possibility. The PRAC concluded that the product information of products containing empagliflozin, empagliflozin/metformin should be amended accordingly. In view of available data on the drug-drug interaction between empagliflozin and lithium from clinical trials and the literature suggestive for causal association, including in some cases a close temporal relationship and positive dechallenge/rechallenge and in view of a plausible mechanism of interaction, the PRAC considers a causal relationship between empagliflozin, empagliflozin / |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                     |            |            |                 | metformin and drug-drug interaction with lithium is at least a reasonable possibility. The PRAC concluded that the product information of products containing empagliflozin, empagliflozin / metformin should be amended accordingly. The CHMP agrees with the scientific conclusions made by the PRAC.                                                                                                     |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0063/G   | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                        | 22/02/2022 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                             |
| WS/2200     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                        | 10/02/2022 | 23/01/2023 | SmPC            | To update sections 4.2, 4.4 and 5.1 of the SmPC to propose a modification of the eGFR threshold in the EU PIs for the fixed dose combinations containing empagliflozin, for Synjardy® (empagliflozin/metformin) and Glyxambi® (empagliflozin/linagliptin) to allow for use of these empagliflozin containing products in patients with T2DM and high cardiovascular risk and an eGFR of ≥30 ml/min/1.73 m2. |
| IAIN/0061/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.7 - Administrative change - Deletion of | 10/12/2021 | 04/03/2022 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of manufacturing sites A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |    | manufacturing sites   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------|
| N/0056    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31/03/2021 | 04/06/2021 | PL |                       |
| IB/0053/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                               | 05/02/2021 | n/a        |    |                       |
| IG/1329   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                        | 22/01/2021 | n/a        |    |                       |

<div style=\"page-break-after: always\"></div>

| IA/0054   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 08/01/2021   | n/a        |      |                                                                                                                                                                                                                                              |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1286/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved | 19/10/2020   | n/a        |      |                                                                                                                                                                                                                                              |
| WS/1780   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of Section 4.4. of the SmPC for Jardiance,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 04/09/2020   | 04/06/2021 | SmPC | Section 4.4. of the SmPC, subsection 'Diabetic ketoacidosis' reflects the increased risk of diabetic ketoacidosis observed for empagliflozin as an adjunct therapy for patients with T1DM. For more information, please refer to the Summary |

<div style=\"page-break-after: always\"></div>

|           | Synjardi and Glyxambi in the SmPC subsection `Diabetic ketoacidosis' to reflect new data from 2 phase III interventional studies (EASE-2 1245.69 and EASE-3 1245.72) from the clinical trial program of empagliflozin as an adjunct to insulin in patients with type 1 diabetes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                       |            |            |                 | of Product Characteristics.                                                                                                                                                                                                                        |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1807   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.5 of the SmPC, in order to add interaction information on interference with the 1,5- anhydroglucitol assay in line with the Company Core Data Sheet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/06/2020 | 04/06/2021 | SmPC            | Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking SGLT2 inhibitors. Use of alternative methods to monitor glycaemic control is advised. |
| IB/0051/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where                                                                                                                | 28/05/2020 | 04/06/2021 | Annex II and PL |                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change   |            |     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0050 | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 05/05/2020 | n/a |

<div style=\"page-break-after: always\"></div>

| IG/1239/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where   | 20/04/2020   | n/a        |             |                                                                                                                                                                                                                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0044              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 30/01/2020   | 01/04/2020 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Synjardy in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IG/1221             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                | 13/03/2020   | n/a        |             |                                                                                                                                                                                                                                                                        |
| IAIN/0045           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                             | 22/11/2019   | 01/04/2020 | SmPC        |                                                                                                                                                                                                                                                                        |
| PSUSA/10388 /201904 | Periodic Safety Update EU Single assessment - empagliflozin, empagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                                                                                     | 31/10/2019   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| WS/1626/G           | This was an application for a group of variations following a worksharing procedure according to                                                                                                                                                                                                                                                                                                                                                                                                           | 25/07/2019   | n/a        |             |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | Commission Regulation (EC) No 1234/2008. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                          |            |     | Article 20 of            |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------|
| IA/0041/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.a - Change in the manufacturing process of finished or intermediate product - Minor change | 07/06/2019 | n/a | the in the manufacturing |
| IB/0039   | B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction                                                                                                                                                                                                                                                                                                                                                                                                                                            | 29/05/2019 | n/a |                          |
| WS/1563/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change in the specification parameters                                                                                                                                                                                                                                                                                                                                     | 28/03/2019 | n/a | B.I.b.1.h -              |

<div style=\"page-break-after: always\"></div>

|                     | and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS   |            |            |             |                                                                                                     |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------|
| IAIN/0038           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                          | 22/02/2019 | 06/06/2019 | SmPC and PL |                                                                                                     |
| PSUSA/10388 /201804 | Periodic Safety Update EU Single assessment - empagliflozin, empagliflozin / metformin                                                                                                                                                                                                                                                                                                                                  | 31/10/2018 | n/a        |             | PRAC Recommendation - maintenance                                                                   |
| IG/0991             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                            | 04/10/2018 | n/a        |             |                                                                                                     |
| IG/0935             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                            | 06/06/2018 | n/a        |             |                                                                                                     |
| WS/1316             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                           | 31/05/2018 | 06/06/2019 | SmPC and PL | The SmPC was updated to include additional information from trial 1245.25 (EMPA-REG OUTCOME study). |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                            |            |            |             | In section 4.8 of Jardiance and Synjardy, changes in eGFR associated with empagliflozin treatment were described. In SmPC section 5.1 of the SmPC for Jardiance, Synjardy and Glyxambi, the effect size of risk reduction in renal and heart failure- related endpoints was added, and in SmPC section 4.4 the statement regarding diabetic ketoacidosis for SGLT-2 inhibitors was aligned. The package leaflet was amended accordingly.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0033             | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                                          | 11/04/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10388 /201704 | Periodic Safety Update EU Single assessment - empagliflozin, empagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                       | 09/11/2017 | 08/01/2018 | SmPC        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10388/201610.                                                                                                                                                                                                                                                                                                 |
| WS/1164             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 30/11/2017 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10388 /201610 | Periodic Safety Update EU Single assessment - empagliflozin, empagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                       | 18/05/2017 | 19/07/2017 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             | PSUSA/10388/201610.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------|
| WS/1173   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                        | 13/07/2017 | n/a        |             |                       |
| IA/0029/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its | 04/07/2017 | n/a        |             |                       |
| WS/1171   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                              | 22/06/2017 | 08/01/2018 | SmPC and PL |                       |

<div style=\"page-break-after: always\"></div>

| WS/1135   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 01/06/2017   | 08/01/2018   | SmPC        |                                                                            |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|----------------------------------------------------------------------------|
| A20/0022  | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 15 April 2016 the PRAC to assess the impact on the benefit-risk balance of canagliflozin containing medicinal products of an increase in amputations, mostly affecting the toes, observed in an ongoing clinical trial (CANVAS) for canagliflozin and a numerical imbalance with regards to amputation events seen in an ongoing renal study CANVAS-R with a similar population as CANVAS. Considering that a class effect cannot be excluded, the European Commission extended on 6 July 2016 the scope of the procedure to include all SGLT2 inhibitors containing medicinal products to allow a review of data from the class. The PRAC was requested to assess the impact thereof on the benefit-risk balance of Invokana, Vokanamet, Forxiga, Edistride, Xigduo, Ebymect, Jardiance and Synjardy and to give its recommendation whether the marketing authorisation of these products should be maintained, varied, suspended or revoked. As the request results from the evaluation of data | 09/02/2017   | 20/04/2017   | SmPC and PL | Please refer to the assessment report: SGLT2 inhibitors - EMEA/H/A-20/1442 |

<div style=\"page-break-after: always\"></div>

|           | CHMP opinion has been be adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee.                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------|
| II/0015   | Modification of the indication for Synjardy to reflect new data on cardiovascular outcomes based on study 1245.25 (EMPA-REG OUTCOME). As a consequence the SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 have been updated. The Package Leaflet and RMP have been updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make some editorial changes. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                     | 26/01/2017 | 03/03/2017 | SmPC and PL | Please refer to the Scientific Discussion Synjardy H-C- 3770-II-15. |
| IG/0771/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 19/01/2017 | n/a        |             |                                                                     |

<div style=\"page-break-after: always\"></div>

|          | manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                    |            |            |             |                                                                                                    |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------|
| WS/0971  | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                       | 15/12/2016 | n/a        |             |                                                                                                    |
| WS/0953  | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                           | 15/12/2016 | n/a        |             |                                                                                                    |
| A31/0013 | Pursuant to Article 31 of Regulation (EC) No 726/2004, the European Commission requested on 25 January 2016 the opinion of the European Medicines Agency on the adequacy of the current recommendations for metformin containing products with respect to the use in patients with moderate renal failure, taking into account the available information on the risk of lactic acidosis. The CHMP | 13/10/2016 | 12/12/2016 | SmPC and PL | Please refer to the assessment report: Metformin containing medicinal products - EMEA/H/A- 31/1432 |

<div style=\"page-break-after: always\"></div>

|         | was requested to assess the impact thereof on the benefit-risk balance of metformin containing products and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended or revoked. The notification for the procedure is appended to this opinion.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0926 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.8 and 5.1 of the SmPC in order to include data from the study 1275.9. In addition, the Worksharing applicant (WSA) took the opportunity to remove optional sentence 'Medicinal product subject to medical prescription' from the Labelling. Moreover, the updated RMP version 8.1 (for Jardiance) and version 6.1 (for Synjardy) have been agreed, as part of this procedure. Furthermore, the WSA took the opportunity to bring the Labelling in line with the latest QRD template version 10. In addition, only for Synjardy, the WSA took the opportunity to make a minor editorial correction in section 4.8 of the SmPC in line with the outcome of EMEA/H/C/PSUSA/00010388/201510 procedure. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 10/11/2016 | 03/03/2017 | SmPC and Labelling | In patients inadequately controlled with metformin and linagliptin 5 mg, treatment with both empagliflozin 10 mg or 25 mg resulted in statistically significant (p<0.0001) reductions in HbA1c and body weight compared to placebo. In addition it resulted in clinically meaningful reductions in FPG, systolic and diastolic blood pressure compared to placebo. In a prespecified subgroup of patients with baseline HbA1c greater or equal than 8.5% the reduction from baseline in HbA1c was -1.3% with empagliflozin 10 mg or 25 mg at 24 weeks (p<0.0001) compared to placebo. The incidence of hypoglycaemia (overall, minor, major) for empagliflozin as add-on to linagliptin and metformin was similar to that in combinations of empagliflozin with other anti-diabetic medicines. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10388 /201604   | Periodic Safety Update EU Single assessment - empagliflozin, empagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 27/10/2016   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0023               | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/10/2016   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| WS/0939               | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.8 and 5.1 of the SmPC in order to include data from study 1276.1 ('A 24-week phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of twice daily oral administration of empagliflozin + metformin compared with the individual components of empagliflozin or metformin in drug naive patients with type 2 diabetes mellitus'). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 21/07/2016   | 12/12/2016 | SmPC        | A factorial design study of 24 weeks duration was conducted to evaluate the efficacy and safety of empagliflozin in drug-naïve patients. Treatment with empagliflozin in combination with metformin (5 mg and 500 mg; 5 mg and 1000 mg; 12.5 mg and 500 mg, and 12.5 mg and 1000 mg given twice daily) provided statistically significant improvements in HbA1c and led to greater reductions in FPG (compared to the individual components) and body weight (compared to metformin). The frequency of patients with hypoglycaemic events (overall, minor or major hypoglycaemia) was similar for empagliflozin and placebo as add on to metformin, and for the combination of empagliflozin with metformin in drug- naïve patients compared to those treated with empagliflozin and metformin as individual components. |
| PSUSA/10388 /201510   | Periodic Safety Update EU Single assessment - empagliflozin, empagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 26/05/2016   | 15/07/2016 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10388/201510.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0018               | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/05/2016   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|          | manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             |                                                                            |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------|
| A20/0001 | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 10 June 2015 the opinion of the European Medicines Agency on the risk of Diabetic ketoacidosis (DKA) in patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors and requested the Agency to assess the impact thereof on the benefit-risk balance of canagliflozin-containing medicinal products (Invokana and Vokanamet), dapagliflozin-containing medicinal products (Forxiga and Xigduo), and empagliflozin-containing medicinal products (Jardiance and Synjardy) and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion should be adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee. The notification for the procedure is appended to this recommendation. | 25/02/2016 | 28/04/2016 | SmPC and PL | Please refer to the assessment report: SGLT2 inhibitors - EMEA/H/A-20/1419 |
| IA/0014  | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 17/02/2016 | n/a        |             |                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0011/G   | was an application for a group of variations.                                                                                              | 07/01/2016   | 28/04/2016   | Annex II and PL   | This                   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|------------------------|
| IB/0010     | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a period supported by real time | 11/12/2015   | n/a          |                   | re-test period/storage |

<div style=\"page-break-after: always\"></div>

|           | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------|
| IB/0009/G | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other | 19/11/2015 | n/a | changes |

<div style=\"page-break-after: always\"></div>

|         | or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0801 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 5.3 and 4.6 of the SmPC in order to update renal development and maturation information after analysis of the non-clinical study 14R018 [n00231757]; in addition, the Worksharing applicant (WSA) took the opportunity to correct minor mistakes in section 5.1 of the SmPC and minor linguistic mistakes in the Spanish product information for Jardiance and in the Finnish, Spanish and Danish product information for Synjardy. The list of local representatives for Spain and Portugal in the Package Leaflet for Jardiance has been updated and the PIs have been brought in line with the latest QRD template version 9.1 for both products. The RMPs have been updated accordingly (final versions Jardiance v.5.1, Synjardy version 3.1). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 22/10/2015 | 28/04/2016 | SmPC, Annex II, Labelling and PL | In a juvenile toxicity study in the rat, when empagliflozin was administered from postnatal day 21 until postnatal day 90, non-adverse, minimal to mild renal tubular and pelvic dilation in juvenile rats was seen only at 100 mg/kg/day, which approximates 11 times the maximum clinical dose of 25 mg. These findings were absent after a 13 weeks drug free recovery period. |
| WS/0800 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.3, 4.4 and 4.5 of the SmPC in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 22/10/2015 | 28/04/2016 | SmPC, Annex II and PL            | Lactic acidosis is a very rare, but serious (high mortality in the absence of prompt treatment), metabolic complication that can occur due to metformin accumulation. Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal                                                                              |

<div style=\"page-break-after: always\"></div>

| order to align the SmPC for Jentadueto and Synjardy to the safety information for the UK metformin label (Glucophage) with regard to tissue hypoxia, lactic acidosis, compromised cardiac or renal function and administration of iodinated contrast agents. In addition, the Worksharing applicant (WSA) took the opportunity to update the list of local representatives for Spain and Portugal in the Package Leaflet for Jentadueto and to bring the PI of Jentadueto in line with the latest QRD template version 9.1. The RMPs (version 3.0 for Synjardy and version 11.0 for Jentadueto) for both products have been updated according to the SmPC changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | data   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        | should be instructed to notify these signs immediately to their physicians if they occur, notably if patients had a good tolerance to the combination including metformin before. The combination should be discontinued, at least temporarily, until the situation is clarified. Reintroduction of the combination should then be discussed taking into account the benefit/risk ratio in an individual basis as well as renal function. In case of lactic acidosis, the patient should be hospitalised immediately. Physicians should alert the patients on the risk and on the symptoms of lactic acidosis.   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0008/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 16/10/2015 | 28/04/2016 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0007   | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16/10/2015 | 28/04/2016 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0003   | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                       | 23/07/2015   | n/a   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IB/0002/G | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 22/07/2015   | n/a   |